Nomura Securities Starts Gilead Sciences (GILD) at Buy; Top Biotech Stock Pick for 2014
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Stocks decline as interest rate uncertainty, earnings weigh
- ASML slides as Q1 sales fall short but firm still on track for 2025 revenue target
- US dollar weakens as market consolidates gains, but uptrend intact
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Crude Inventory Rose 2.7 Million Barrels Last Week, Says EIA
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
Nomura Securities Starts Amgen (AMGN) at Neutral, $131 PT
January 8, 2014 8:00 AM ESTNomura Securities initiates coverage on Amgen (NASDAQ: AMGN) with a Neutral. PT $131.00.
Analyst Ian Somaiya comments: "Amgen's is the world's largest biotechnology company by revenue, with 2013E sales of $18.4bn spread across three main areas of focus: chronic kidney disease (CKD),... More
Nomura Securities Starts BioMarin Pharmaceutical Inc. (BMRN) at Neutral, $75 PT
January 8, 2014 7:56 AM ESTNomura Securities initiates coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a Neutral. PT $75.00.
"BioMarin's diversified product portfoliowith four marketed drugs, an advanced pipeline with three drugs in Phase III trials and a focus on high margin ultra orphan diseasessupports our... More
